Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy.

Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now? Support Care Cancer (2010) 1.11

The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol (2013) 1.06

Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33). Support Care Cancer (2010) 0.85

Real-world impact of granulocyte-colony stimulating factor on febrile neutropenia. Curr Oncol (2013) 0.79

Breakthrough febrile neutropenia and associated complications among elderly cancer patients receiving myelosuppressive chemotherapy for solid tumors and lymphomas. Support Care Cancer (2013) 0.75

Incidence of neutropenia, chemotherapy delivery, and use of colony-stimulating factor in patients with non-Hodgkin lymphoma of different age groups. Leuk Lymphoma (2011) 0.75

Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med (2011) 12.52

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol (2006) 11.26

Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2011) 7.24

Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol (2009) 7.21

Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer (2006) 5.03

Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med (2008) 4.71

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70

Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol (2012) 4.42

Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. J Clin Oncol (2013) 4.28

Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood (2008) 4.06

Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol (2007) 4.06

American Society of Clinical Oncology 2013 top five list in oncology. J Clin Oncol (2013) 4.03

Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol (2013) 3.92

Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer (2006) 3.86

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol (2006) 3.52

Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol (2011) 3.45

Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer (2007) 3.27

Retracted Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA (2008) 3.26

Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer (2004) 3.15

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol (2011) 3.06

Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol (2011) 2.76

Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol (2007) 2.76

NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Canc Netw (2011) 2.73

Vaccination coverage rates in eleven European countries during two consecutive influenza seasons. J Infect (2009) 2.72

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol (2012) 2.72

Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer (2011) 2.67

Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res (2010) 2.66

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol (2010) 2.54

A systematic literature review and meta-analysis of randomized clinical trials of parenteral glutamine supplementation. Clin Nutr (2012) 2.47

Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol (2008) 2.43

Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol (2012) 2.38

Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care (2005) 2.37

Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors. Cancer (2009) 2.35

Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med (2005) 2.25

Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer (2005) 2.20

Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy. J Clin Oncol (2006) 2.17

Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol (2005) 2.13

The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients. Transfusion (2007) 2.12

Breast carcinoma during pregnancy. International recommendations from an expert meeting. Cancer (2006) 2.04

Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol (2006) 2.03

Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol (2012) 2.02

Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat (2007) 2.01

Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J Clin Oncol (2007) 1.92

Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer (2012) 1.91

Influenza vaccination coverage rates in five European countries during season 2006/07 and trends over six consecutive seasons. BMC Public Health (2008) 1.89

Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med (2008) 1.85

Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol (2011) 1.83

International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol (2003) 1.83

American Society of Clinical Oncology clinical practice guidelines: opportunities and challenges. J Clin Oncol (2008) 1.75

Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat (2010) 1.73

Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol (2010) 1.71

Preventive therapy for breast cancer: a consensus statement. Lancet Oncol (2011) 1.69

Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. Thromb Res (2010) 1.66

Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw (2008) 1.65

Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer (2008) 1.62

Cost-effectiveness of invasive versus medical management of elderly patients with chronic symptomatic coronary artery disease. Findings of the randomized trial of invasive versus medical therapy in elderly patients with chronic angina (TIME). Eur Heart J (2004) 1.60

Breast cancer in the elderly. J Clin Oncol (2007) 1.60

Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. Ann Surg Oncol (2012) 1.56

A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer (2007) 1.54

Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol (2010) 1.51

Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Oncogene (2002) 1.48

Locoregional treatment of primary breast cancer: consensus recommendations from an International Expert Panel. Cancer (2010) 1.47

Trastuzumab single-drug therapy after failure of cytotoxic treatment for metastatic breast cancer. Onkologie (2010) 1.45

Importance of granulocyte colony-stimulating factor prophylaxis in therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone given every 14 days for diffuse large B-cell lymphoma in routine clinical practice. Leuk Lymphoma (2012) 1.42

Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. J Urol (2009) 1.40

Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research. Genet Med (2012) 1.39

Variation in the cost of medications for the treatment of colorectal cancer. Am J Manag Care (2008) 1.39

Length of stay and mortality associated with febrile neutropenia among children with cancer. J Clin Oncol (2005) 1.38

Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer (2008) 1.37

Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial. PLoS One (2013) 1.34

Combination versus sequential single-agent therapy in metastatic breast cancer. Oncologist (2002) 1.33

Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat (2011) 1.32

Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol (2008) 1.29

Docetaxel-related side effects and their management. Eur J Oncol Nurs (2009) 1.29

Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group. J Clin Oncol (2008) 1.27

Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure. Ann Intern Med (2014) 1.27

Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat (2006) 1.25

Undertreatment of cancer patients with chemotherapy is a global concern. J Oncol Pract (2008) 1.23

Myeloid growth factors. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 1.23

Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. Br J Haematol (2008) 1.22

Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol (2009) 1.21

Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. J Natl Cancer Inst (2013) 1.21

Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Support Care Cancer (2004) 1.16

Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst (2004) 1.15

Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health (2008) 1.14

Biosimilars: are they ready for primetime in the United States? J Natl Compr Canc Netw (2011) 1.14

Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. J Natl Compr Canc Netw (2003) 1.14

Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat (2012) 1.14

Margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive breast cancer: American Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus guideline. J Clin Oncol (2014) 1.13

Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies. Breast Cancer Res Treat (2010) 1.13

Myeloid growth factors. J Natl Compr Canc Netw (2013) 1.13

American Society of Clinical Oncology Clinical Practice Guidelines: formal systematic review-based consensus methodology. J Clin Oncol (2012) 1.12

Impact of multifocal or multicentric disease on surgery and locoregional, distant and overall survival of 6,134 breast cancer patients treated with neoadjuvant chemotherapy. Ann Surg Oncol (2014) 1.12

Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Res (2009) 1.12

Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial. Ann Surg Oncol (2006) 1.12

Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis. J Clin Oncol (2011) 1.12

Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer (2007) 1.11

ASCO Clinical Practice Guidelines: Past, Present and Future. J Oncol Pract (2008) 1.10

Learning from failure--rationale and design for a study about discontinuation of randomized trials (DISCO study). BMC Med Res Methodol (2012) 1.10